Success Metrics

Clinical Success Rate
74.2%

Based on 293 completed trials

Completion Rate
74%(293/395)
Active Trials
194(27%)
Results Posted
83%(242 trials)
Terminated
102(14%)

Phase Distribution

Ph phase_4
10
1%
Ph not_applicable
11
2%
Ph phase_1
180
25%
Ph phase_2
337
48%
Ph phase_3
158
22%
Ph early_phase_1
4
1%

Phase Distribution

184

Early Stage

337

Mid Stage

168

Late Stage

Phase Distribution700 total trials
Early Phase 1First-in-human
4(0.6%)
Phase 1Safety & dosage
180(25.7%)
Phase 2Efficacy & side effects
337(48.1%)
Phase 3Large-scale testing
158(22.6%)
Phase 4Post-market surveillance
10(1.4%)
N/ANon-phased studies
11(1.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

68.6%

293 of 427 finished

Non-Completion Rate

31.4%

134 ended early

Currently Active

194

trials recruiting

Total Trials

709

all time

Status Distribution
Active(215)
Completed(293)
Terminated(134)
Other(67)

Detailed Status

Completed293
Recruiting109
Terminated102
Active, not recruiting85
unknown65
Withdrawn32

Development Timeline

Analytics

Development Status

Total Trials
709
Active
194
Success Rate
74.2%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (0.6%)
Phase 1180 (25.7%)
Phase 2337 (48.1%)
Phase 3158 (22.6%)
Phase 410 (1.4%)
N/A11 (1.6%)

Trials by Status

withdrawn325%
active_not_recruiting8512%
not_yet_recruiting203%
unknown659%
recruiting10915%
completed29341%
suspended20%
enrolling_by_invitation10%
terminated10214%

Recent Activity

Clinical Trials (709)

Showing 20 of 709 trialsScroll for more
NCT06561685Phase 1

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

Recruiting
NCT07190248Phase 3

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Recruiting
NCT06459180Phase 3

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Active Not Recruiting
NCT06694454Phase 1

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Recruiting
NCT06793215Phase 3

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Recruiting
NCT04410796Phase 2

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

Recruiting
NCT05261399Phase 3

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

Active Not Recruiting
NCT06096844Phase 3

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Recruiting
NCT05198830Phase 2

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Recruiting
NCT02194738Not Applicable

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Active Not Recruiting
NCT06632327Phase 3

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

Recruiting
NCT07486817Phase 2

Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

Recruiting
NCT04083599Phase 1

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Active Not Recruiting
NCT03793179Phase 3

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

Active Not Recruiting
NCT06305754Phase 3

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Active Not Recruiting
NCT07642024Phase 2

A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)

Recruiting
NCT05001880Phase 2

Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

Recruiting
NCT05067283Phase 1

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

Recruiting
NCT07586202Phase 2

A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC

Recruiting
NCT06772623Phase 1

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
709